"...an increase of other income of 4.8 million for 2020 relating to research and development income in connection with our Australian clinical trial activities. Our cash position at the end of 30th 2020 was 29.2 million compared to 22.2 million at September 30th 2019. We are also reporting today our cash position has increased to 47.6 million as of today which gives us sufficient cash for approximately the next 24 months."